Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
99.8 USD | -0.31% | +3.36% | +25.47% |
Apr. 11 | Mizuho Securities Adjusts Price Target on Glaukos to $100 From $85, Maintains Neutral Rating | MT |
Apr. 11 | Glaukos Insider Sold Shares Worth $6,008,359, According to a Recent SEC Filing | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company is in debt and has limited leeway for investment
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+25.47% | 5.02B | B+ | ||
+12.46% | 128B | A- | ||
-9.04% | 10.51B | A- | ||
+0.91% | 8.71B | C | ||
+16.33% | 7B | C | ||
+7.26% | 3.39B | C- | ||
-1.08% | 3.02B | B- | ||
-8.73% | 2.07B | - | - | |
-10.15% | 2.06B | - | ||
-22.81% | 1.73B | - | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GKOS Stock
- Ratings Glaukos Corporation